Clinical Course of Neurologic Adverse Events Associated With Immune Checkpoint Inhibitors
More than half of the patients with n-irAEs who survived the acute phase developed a chronic condition. Patients with chronic n-irAEs were at higher risk of death, mainly due to cancer progression. Future studies are needed to further characterize chronic n-irAEs and identify optimal long-term management strategies.
Authors
- Simone Rossi (ORCID: https://orcid.org/0000-0001-7044-983X)
- Matteo Gastaldi (ORCID: https://orcid.org/0000-0003-2288-2000)
- Antonio Farina (ORCID: https://orcid.org/0000-0002-5551-0185)
- Flavia Baccari (ORCID: https://orcid.org/0000-0002-2148-9664)
- Luigi Zuliani (ORCID: https://orcid.org/0000-0001-7922-9024)
- Matteo Garibaldi (ORCID: https://orcid.org/0000-0003-1830-2886)
- Sara Cornacchini (ORCID: https://orcid.org/0000-0003-2918-4627)
- Irene Florean (ORCID: https://orcid.org/0000-0001-9406-9794)
- Maria Guarino (ORCID: https://orcid.org/0000-0002-8894-2187)
- Laura Fionda (ORCID: https://orcid.org/0000-0002-8813-2272)
- Antonio Lauletta (ORCID: https://orcid.org/0000-0001-8853-7280)
- Enrico Marchioni (ORCID: https://orcid.org/0000-0003-0414-8128)
- Alberto Vogrig (ORCID: https://orcid.org/0000-0002-3652-7061)
- Valentina Damato (ORCID: https://orcid.org/0000-0003-1740-4522)
- Antonio Malvaso (ORCID: https://orcid.org/0000-0001-9691-0890)
- Alessandro Dinoto (ORCID: https://orcid.org/0000-0002-3249-4792)
- Rita Rinaldi (ORCID: https://orcid.org/0000-0002-4564-7284)
- Corrado Zenesini (ORCID: https://orcid.org/0000-0002-9855-8197)
- Sara Mariotto (ORCID: https://orcid.org/0000-0002-7806-3103)
- Luca Diamanti (ORCID: https://orcid.org/0000-0002-4540-6886)
Institutions
- Université Claude Bernard Lyon 1 (FR)
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Fondazione Istituto Neurologico Nazionale Casimiro Mondino (IT)
Publication Details
- Journal
- Neurology Neuroimmunology & Neuroinflammation
- Published
- 2024-09-19
- DOI
- https://doi.org/10.1212/nxi.0000000000200314
- Citations
- 24
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 6.78